Step 1: Glucagon-like peptide-2 (GLP-2) is a key intestinotrophic growth factor that mediates intestinal adaptation - it promotes mucosal growth and improves fluid and nutrient absorption.
Step 2: Teduglutide is a recombinant GLP-2 analog. By acting like GLP-2, it expands the absorptive surface of the remaining bowel.
Step 3: It is FDA approved to treat short bowel syndrome in adults who need additional parenteral (I.V.) nutrition, reducing their dependence on it by improving fluid absorption.
Step 4: GLP-1 analogs (option c) are used for diabetes, HT1a refers to a serotonin receptor, and C-peptide is a by-product of insulin synthesis - none describe teduglutide, so the answer is the GLP-2 analog option.